Searched for
MYELODYSPLASTIC SYNDROME
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...- A waterfall once led to memory loss for Amrish Puri on Ajay Devgn's movie; everyone was confusedAmrish Puri once experienced temporary memory loss while filming a scene under a waterfall for an Ajay Devgn movie. Kajol recently shared t...
- Biocon shares up 3% after US FDA nod for key cancer drugsBiocon share price: Shares of Biocon Ltd rose 3% after Biocon Pharma received FDA approvals for cancer drugs Lenalidomide and Dasatinib, en...
- General Hospital star John J. York battles with Myelodysplastic Syndrome —What is MDS? Know causes, symptoms & treatmentGeneral Hospital actor John J. York has disclosed that he is currently receiving treatment for two blood and bone marrow disorders. In a vi...
- Good Morning America host Robin Roberts weds longtime GF Amber Laign; celebs congratulate coupleBoth Robin Roberts and Amber Laign are cancer survivors and have been together since 2005. Here’s what we know of their wedding.
- Deadpool star Ryan Reynolds sends heart-warming video message to 6-year-old boy in need of life-saving treatment. Watch hereHollywood actor and Wrexham co-owner Ryan Reynolds posted a video supporting a boy diagnosed with Pre-Leukemia and needs immediate treatmen...
- Buy Natco Pharma, target price Rs 1021: ICICI SecuritiesNatco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 15529.31 Crore) operating in Pharmaceutic...
- Natco Pharma announces launch of first generic of top selling cancer drug RevlimidRevlimid had annual sales of $2.3 billion as of December 2021, according to IQVIA data. The generic version of Revlimid will be available i...
- Zydus Cadila gets USFDA nod to market generic cancer drug in USThe company has received final approval from the US Food and Drug Administration (USFDA) to Decitabine for Injection in the strength of 50 ...
- Dr Reddy's launches cancer drug in Canada"Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada's Multiple Myeloma ...
- Natco Pharma shares hit upper circuit. Here's whyThe Hyderabad-based firm said the first dose under the phase-III trials was given to a patient in the city-based Yashoda Hospitals.
- Natco Pharma gets American drug regulator's nod for generic cancer treatment drugNatco, along with its marketing partner Arrow International previously settled the Paragraph IV litigation related to the product with Celg...
- Natco Pharma soars 17% as path to launch Revlimid generic clearsNatco Pharma would be the first company to launch Revlimid (lenalidomide) in March 2022 as Dr Reddy’s settlement clears the path for the co...
- Google pays tribute to legendary actor Amrish Puri on 87th birth anniversary with doodlePuri passed away on December 27, 2004, due to myelodysplastic syndrome.
- Wockhardt jumps 4% on USFDA nod for new injectionWockhardt will launch this product in the US within a short period of time.
- 'Fukrey' actor Ashraf-ul-Haq passes awayAshraf-ul-Haq, best known for his roles in 'Fukrey' and 'Traffic Signal', died today at the age of 45 after losing a battle with a blood-re...
- Intas launches cheaper generic blood cancer drugIntas is manufacturing Azadine at its Ahmedabad facility, which operates in compliance with global regulatory standards like USFDA, MHRA an...
- Intas Pharmaceuticals prices generic onco-drug at one-fifth of current costIn MDS, the bone marrow does not make enough healthy blood cells and there are abnormal cells present, leading to leukaemia in advanced sta...
- Brokerages raise price target on Dr Reddy's to as high as Rs 2,720 on FDA nodBrokerages see the FDA approval to Dr Reddy’s Laboratories (DRL) for generic Vidaza as a positive for the company.
- Cryobanks India aims Rs 300 crore revenue in 4 yearsCryobanks International India expects to clock revenue of Rs 300 crore by 2011-12 as it looks to expand its presence in the country.
Load More
